MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies

Journal of Thoracic Oncology 2017 October [Epub ahead of print] [Link]

Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS

Abstract

Chimeric antigen receptor (CAR) T cells are patient T cells that are transduced with genetically engineered synthetic receptors to target a cancer cell surface antigen. The remarkable clinical response rates achieved by adoptive transfer of T cells that target CD19 in patients with leukemia and lymphoma have led to a growing number of clinical trials exploring CAR T-cell therapy for solid tumors. Herein, we review the evolution of adoptive T-cell therapy, highlight advances in CAR T-cell therapy for thoracic malignancies, and summarize the targets being investigated in clinical trials for patients with lung cancer, malignant pleural mesothelioma, and esophageal cancer. We further discuss the barriers to successfully translating CAR T-cell therapy for solid tumors and present strategies that have been investigated to overcome these hurdles.

Both comments and trackbacks are currently closed.